Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Dosing Regimens in Wet AMD
NCT04113538Phase 3Unknown
- Sponsor
- Mablink Bioscience
- Start
- Jul 2019
- Primary completion
- Jan 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Mablink Bioscience. Primary endpoints: Best Corrected Visual Acuity at 52 weeks and Number of Injections at 52 weeks. Status: unknown.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04113538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113538.